<DOC>
	<DOCNO>NCT01955200</DOCNO>
	<brief_summary>The purpose study determine patient receive stent implantation present low response regular anti-platelet treatment , whether 1-month intensified anti-platelet treatment replace clopidogrel ticagrelor ( TCL ) superior double dose clopidogrel add cilostazol .</brief_summary>
	<brief_title>Optimal Anti-platelet Treatment Patients With Clopidogrel Low Response</brief_title>
	<detailed_description>Optimal anti-Platelet Treatment patient stent IMplantation And clopidogrel Low response : OPTIMAL study Previous study show dual anti-platelet treatment ( DAPT ) aspirin clopidogrel provide 20 % risk reduction cardiovascular death , myocardial infarction stroke compare aspirin alone patient acute coronary syndrome ( ACS ) 1-4 . However , 5~40 % patient report low response clopidogrel , associate high risk cardiovascular events5 . Thus , great clinical value explore intensified anti-platelet regimen improve inhibition platelet function clopidogrel low responder . Several intensified anti-platelet protocol evaluate non-selected ACS patient . OASIS-7 show 600mg load dose 1-week double dose clopidogrel associate 42 % risk reduction definite stent thrombosis compare regular DAPT6 ; meta-analysis demonstrate cilostazol base triple anti-platelet treatment ( TAPT ) reduce risk late loss minimal lumen diameter ( MLD ) binary angiographic restenosis well target lesion revascularization ( TLR ) target vessel revascularization ( TVR ) compare regular DAPT patient undergo coronary stent implantation ; PLATO study show ticagrelor ( TCL ) base DAPT associate significantly low incidence myocardial infarction cardiovascular death compare clopidogrel base DAPT , difference mainly appear first 30 days7 . However , still study investigate mention method optimal one improve anti-platelet effect well clinical outcome clopidogrel low responder . The investigator hypotheses patient receive stent implantation present clopidogrel low response , 1-month intensified anti-platelet treatment replace clopidogrel ticagrelor ( TCL ) superior double dose clopidogrel add cilostazol regard inhibition platelet aggregation response adenosine diphosphate ( ADP ) . Inclusion criterion : 1 . Successively recruit patient receive stent implantation ; 2 . Patient age &gt; 18 year ≦80 year old ; 3 . Signed inform consent . Exclusion criterion : 1 . Allergy intolerance ASA , clopidogrel TCL ; 2 . Subjects high risk bleeding ( e.g . platelet count &lt; 80*109/L , know bleed diathesis , active peptic ulcer ) ; 3 . Patients plan take warfarin drug potentially could interfere anti-platelet effect ASA ( e.g . non-steroidal anti-inflammatory drug ) , clopidogrel TCL ( e.g . strong CYP3A inhibitor CYP3A inducer ) . Randomization : All patient take 300mg load dose clopidogrel plus 100mg daily ASA 75mg daily clopidogrel admission . Patients recruit percutaneous coronary intervention ( PCI ) . Light transmittancy aggregation ( LTA ) response 5μM ADP measure 5 day take load dose clopidogrel . Patients randomize follow 4 group receive either regular DAPT different intensify anti-platelet treatment 1 month inhibition platelet aggregation ( IPA ) 60 % . All patient return regular DAPT ( ASA 100mg daily , clopidogrel 75mg daily ) 11 month 1-month intensified treatment . Patients IPA &gt; 60 % receive regular DAPT 5th group . 1 . Intensified anti-platelet treatment-1 : ASA 100mg daily + Ticagrelor 90mg Bid 2 . Intensified anti-platelet treatment-2 : ASA 100mg daily + Clopidogrel 150mg daily 3 . Intensified anti-platelet treatment-3 : ASA 100mg daily + Clopidogrel 75mg daily + cilostazol 150mg Bid 4 . Regular DAPT ( IPA≦60 % ) : ASA 100mg daily + Clopidogrel 75mg daily 5 . Regular DAPT ( IPA &gt; 60 % ) : ASA 100mg daily + Clopidogrel 75mg daily Sample size calculation : The IPA ticagrelor response ADP report 88±15 % , 5 % 2-side alpha , 30 patient group would offer 80 % power demonstrate result ticagrelor superior group . According previous study , assume ratio clopidogrel low response 10 % , 1200 patient require reach statistical significance . To avoid drop-out , sample size set 1350 patient . Tests : 1 . ADP-induced platelet aggregation : Light transmittancy aggregation ( LTA ) response 5μM ADP . 2 . Arachidonic acid ( AA ) -induced platelet aggregation : Light transmittancy aggregation ( LTA ) response 1mM AA . 3 . Blood sample point : baseline ( 5 day take load dose clopidogrel ) , 1month randomization . Clinical follow-up : Time point : 1month , 6month , 1year randomization . Primary endpoint : 1 . Inhibition platelet aggregation ( IPA ) response 5μM ADP determine light transmittancy aggregometer ( LTA ) 1-month intensified anti-platelet treatment . Secondary endpoint : 1 . Clinical efficacy : death , non-fatal myocardial infarction , ischemic stroke , revascularization , stent thrombosis ( ARC definition ) ; 2 . Safety : minor , moderate , major bleeding .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Successively recruit patient receive stent implantation ; 2 . Patient age &gt; 18 year ≦80 year old ; 3 . Signed inform consent . 1 . Allergy intolerance ASA , clopidogrel TCL ; 2 . Subjects high risk bleeding ( e.g . platelet count &lt; 80*109/L , know bleed diathesis , active peptic ulcer ) ; 3 . Patients plan take warfarin drug potentially could interfere antiplatelet effect ASA ( e.g . nonsteroidal antiinflammatory drug ) , clopidogrel TCL ( e.g . strong CYP3A inhibitor CYP3A inducer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Stent implantation</keyword>
	<keyword>Clopidogrel low response</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Cilostazol</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>